List of Lumify drug patents

Lumify is owned by Bausch And Lomb Inc.

Lumify contains Brimonidine Tartrate.

Lumify has a total of 2 drug patents out of which 0 drug patents have expired.

Lumify was authorised for market use on 22 December, 2017.

Lumify is available in solution/drops;ophthalmic dosage forms.

Lumify can be used as relieves redness of the eye due to minor eye irritations.

The generics of Lumify are possible to be released after 14 July, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8293742 BAUSCH AND LOMB INC Preferential vasoconstriction compositions and methods of use
Jul, 2030

(7 years from now)

US9259425 BAUSCH AND LOMB INC Compositions and methods for eye whitening
Jul, 2030

(7 years from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 22 December, 2017

Treatment: Relieves redness of the eye due to minor eye irritations

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of LUMIFY before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in